Their review highlighted that both innate and adaptive immune dysregulation in major depressive disorder (MDD) lead to persistent elevation of CRP and IL-6, promoting microglial activation and impaired synaptic plasticity, which hypothetically could hinder the response to antidepressants [12]. The gene discussed is IL6; the disease is major depressive disorder.